Sequent Medical, Inc. Launches VIA Microcatheter
ALISO VIEJO, Calif., Dec. 11, 2012 /PRNewswire/ — Sequent Medical, Inc. announced today it has received CE mark for the VIA(TM) Microcatheter and is initiating commercial introduction of this new product family in select markets.
The VIA will be used for delivery and deployment of Sequent’s WEB® Aneurysm Embolization System, which is utilized to treat cerebral aneurysms. The VIA is currently available in two models, the VIA and the VIA PLUS.
“The VIA Microcatheter provides an optimal combination of properties for stable WEB placement, retrieval and navigability and will enable physicians to treat a broader range of aneurysm with the WEB,” said PD Dr. med. Werner Weber, Head of the Department of Radiology and Interventional Neuroradiology, Klinikum Vest, Knappschaftskrankenhaus, Recklinghausen, Germany.
“Combined with planned additions to our WEB platform, the VIA demonstrates Sequent Medical’s ongoing commitment to developing a broad portfolio of innovative catheter-based technologies for neurovascular specialists and their patients,” said Tom Wilder, President and Chief Executive Officer.
About Sequent Medical, Inc.
Sequent Medical, Inc. (www.sequentmedical.com) is a privately held medical-device company that is dedicated to the development of innovative catheter-based neurovascular technologies. The WEB Aneurysm Embolization System and VIA Microcatheter have both received the CE mark. They are not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.
About The WEB Aneurysm Embolization System
Building upon the foundation of endovascular embolic coils, the WEB is a low porosity intrasaccular neurovascular embolization device that is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis. The WEB enables physicians to treat intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.
SOURCE Sequent Medical Inc.